Keytruda vs Kisqali
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Keytruda | US Kisqali | |
|---|---|---|
| Generic name | pembrolizumab | ribociclib |
| Drug class | PD-1 Inhibitor (Immunotherapy) | CDK4/6 Inhibitor |
| Treats | Multiple cancers | HR-positive, HER2-negative breast cancer |
| Category | Oncology | Oncology |
| Manufacturer | Merck | Novartis |
| Year approved | 2014 | 2017 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $260M | $80M |
| Common side effects | Immune-related side effects, Fatigue, Rash, Diarrhea | Low white blood cells, Nausea, Fatigue, Heart rhythm changes (QT) |
Frequently asked questions
Is Keytruda or Kisqali better?
Neither is universally "better." Keytruda (pembrolizumab) and Kisqali (ribociclib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Keytruda and Kisqali?
Keytruda is a PD-1 Inhibitor (Immunotherapy) made by Merck, while Kisqali is a CDK4/6 Inhibitor made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Keytruda has the larger estimated TV advertising budget of the two.